- Home
- SOWG vs SABS Comparison
SOWG vs SABS Comparison
Compare SOWG & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- SABS
- Stock Information
- Founded
- SOWG 2010
- SABS 2014
- Country
- SOWG United States
- SABS United States
- Employees
- SOWG N/A
- SABS N/A
- Industry
- SOWG Packaged Foods
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- SOWG Consumer Staples
- SABS Health Care
- Exchange
- SOWG Nasdaq
- SABS Nasdaq
- Market Cap
- SOWG 22.6M
- SABS 19.0M
- IPO Year
- SOWG N/A
- SABS N/A
- Fundamental
- Price
- SOWG $2.43
- SABS $1.63
- Analyst Decision
- SOWG Strong Buy
- SABS Strong Buy
- Analyst Count
- SOWG 2
- SABS 5
- Target Price
- SOWG $23.00
- SABS $12.40
- AVG Volume (30 Days)
- SOWG 33.8K
- SABS 75.8K
- Earning Date
- SOWG 03-21-2025
- SABS 03-28-2025
- Dividend Yield
- SOWG N/A
- SABS N/A
- EPS Growth
- SOWG N/A
- SABS N/A
- EPS
- SOWG 0.21
- SABS N/A
- Revenue
- SOWG $40,130,971.00
- SABS $1,512,723.00
- Revenue This Year
- SOWG $122.17
- SABS N/A
- Revenue Next Year
- SOWG N/A
- SABS N/A
- P/E Ratio
- SOWG $11.63
- SABS N/A
- Revenue Growth
- SOWG 508.45
- SABS N/A
- 52 Week Low
- SOWG $1.98
- SABS $1.45
- 52 Week High
- SOWG $24.83
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- SOWG 46.21
- SABS 38.93
- Support Level
- SOWG $2.20
- SABS $1.45
- Resistance Level
- SOWG $2.36
- SABS $1.74
- Average True Range (ATR)
- SOWG 0.19
- SABS 0.17
- MACD
- SOWG 0.01
- SABS 0.05
- Stochastic Oscillator
- SOWG 47.13
- SABS 40.27
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free granola products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.